BMS-986527 for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with clear cell renal cell carcinoma (a type of kidney cancer). Participants should be in generally good health aside from their cancer. People with certain other medical conditions or who are unable to follow the study procedures may not be eligible.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986527
- Cabozantinib
- Nivolumab
Trial Overview
The study is testing a new drug called BMS-986527, alone or possibly combined with Nivolumab and Cabozantinib, to see if it is safe and tolerable for people with this type of kidney cancer.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Lead Sponsor
Bristol-Myers Squibb
Industry Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.